Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC38868 structure
    GC38868TRAF-STOP inhibitor 6877002
    CAS: 433249-94-6
    纯度: >99.50% / >98.00%

    TRAF-STOP inhibitor 6877002是一种抑制CD40-TRAF6相互作用的选择性抑制剂(TRAF-STOPs)。

  • GC38927 structure
    GC38927MCL-1/BCL-2-IN-2
    CAS: 2163793-44-8
    纯度: >98.00%

    MCL-1/BCL-2-IN-2 (Compound 6) 是一种有效的选择性 Mcl-1 和 Bcl-2 抑制剂。

  • GC38928 structure
    GC38928MCL-1/BCL-2-IN-3
    CAS: 2163793-55-1
    纯度: >99.00%

    MCL-1/BCL-2-IN-3 (Compound 2) 是一种有效的选择性 Mcl-1 和 Bcl-2 抑制剂,IC50 分别为 5.95 和 4.78 μM。

  • GC38941 structure
    GC38941PROTAC Bcl2 degrader-1
    CAS: 2378801-85-3
    纯度: >98.50%

    PROTAC Bcl2 degrader-1 (Compound C5) 是一种 PROTAC,通过将 E3 连接酶 cereblon 的配体 pomalidomide 引入到 Mcl-1/Bcl-2 的双重抑制剂 Nap-1,来有效、特异性地诱导 Bcl-2 (IC50,4.94 μM;DC50,3.0 μM) 和 Mcl-1 (IC50,11.81 μM) 的降解。

  • GC38943 structure
    GC38943PROTAC Mcl1 degrader-1
    CAS: 2163793-38-0
    纯度: >98.00%

    PROTAC Mcl1 degrader-1 (compound C3) 是一种靶向嵌合体的蛋白水解 (PROTAC),是有效,选择性的 Mcl-1 抑制剂,IC50 为 0.7 μM。PROTAC Mcl1 degrader-1 通过将具有微摩尔范围亲和力的 E3 连接酶脑 (CRBN) 结合配体 pomalidomide 引入 Mcl-1 抑制剂 S1-6 来诱导 Mcl-1 的泛素化和蛋白酶体降解。

  • GC38967 structure
    GC38967Lycorine
    CAS: 476-28-8
    纯度: >98.00%

    An alkaloid with diverse biological activities

  • GC38969 structure
    GC38969Neogambogic acid
    CAS: 93772-31-7

    Neogambogic acid 是藤黄的有效成分,可诱导细胞凋亡并具有抗癌作用。 Neogambogic acid 对耐甲氧西林的金黄色葡萄球菌 (MRSA) 具有明显的抑制活性。

  • GC38970 structure
    GC38970Sophoraflavanone G
    CAS: 97938-30-2
    纯度: >98.00%

    A flavonoid with diverse biological activities

  • GC38973 structure
    GC38973Osmundacetone
    CAS: 37079-84-8

    Osmundacetone 是从 Osmundae Rhizoma 中分离出的一种天然产物。

  • GC39022 structure
    GC39022Tetramethylcurcumin
    CAS: 52328-97-9

    Tetramethylcurcumin (FLLL31), a small-molecule signal transducer and activator of transcription 3 (STAT3) inhibitor derived from curcumin, binds selectively to Janus kinase 2 and the STAT3 Src homology-2 domain, which serve crucial roles in STAT3 dimerization and signal transduction.

  • GC39040 structure
    GC39040Taraxerol acetate
    CAS: 2189-80-2

    Taraxerol acetate 是 COX-1 和 COX-2 抑制剂, IC50 值分别为 116.3 μM 和 94.7μM。Taraxerol acetate 具有抗癌作用并诱导细胞凋亡(apoptosis)。

  • GC39041 structure
    GC39041Polyporenic acid C
    CAS: 465-18-9

    Polyporenic acid C 是从 P. cocos 中分离出的羊毛甾烷型三萜。Polyporenic acid C 通过死亡受体介导的凋亡途径诱导细胞凋亡 (apoptosis),而无需线粒体的参与。 Polyporenic acid C 是治疗肺癌的有前途的药物。

  • GC39062 structure
    GC39062Kumatakenin
    CAS: 3301-49-3
    纯度: >98.00%

    Kumatakenin是一种从丁香或黄芪中分离得到的黄酮类天然产物,具有口服活性的凋亡诱导剂和自噬抑制剂。

  • GC39063 structure
    GC39063Prosapogenin A
    CAS: 19057-67-1
    纯度: >98.00%

    Prosapogenin A 是藜芦中的天然产物,通过抑制 STAT3 信号通路和糖酵解,在体外诱导人癌细胞凋亡。

  • GC39069 structure
    GC39069Poncirin
    CAS: 14941-08-3
    纯度: >98.00%

    A flavonoid glycoside with diverse biological activities

  • GC39070 structure
    GC39070Negletein
    CAS: 29550-13-8

    Negletein 是一种神经保护剂,可增强神经生长因子的作用并诱导 PC12 细胞中的神经突向外生长。Negletein 通过抑制 TNF-α 和 IL-1β 表现出有希望的抗炎活性,其 IC50 值分别为 16.4 和 10.8 μM。

  • GC39094 structure
    GC39094Thonningianin A
    CAS: 271579-11-4
    纯度: >99.50%

    Thonningianin A 是一种鞣花素,从非洲草药通宁宁的甲醇提取物中分离得到。Thonningianin A 的抗氧化特性包括自由基清除、抗超氧物生成和金属螯合作用。具有抗癌活性。

  • GC39135 structure
    GC39135Ranaconitine
    CAS: 1360-76-5

    An alkaloid with analgesic and anesthetic activities

  • GC39152 structure
    GC391529-ING-41
    CAS: 1034895-42-5
    纯度: >98.00%

    9-ING-41是一种选择性且强效的GSK-3β抑制剂,IC 50 值为0.71μM。

  • GC39155 structure
    GC39155PI-273
    CAS: 925069-34-7
    纯度: >98.00%

    PI-273, the first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM, can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis.

  • GC39167 structure
    GC39167VBIT-4
    CAS: 2086257-77-2
    纯度: >98.00%

    VBIT-4是电压依赖性阴离子通道1(VDAC1)寡聚化的抑制剂,对纯化VDAC1的K d 值为3μM。

  • GC39169 structure
    GC39169CC-92480
    CAS: 2259648-80-9
    纯度: >98.00% / >99.00%

    CC-92480(Mezigdomide)是一种新型的Cereblon(CRBN)E3连接酶调节剂(CELMoD),常以分子胶的方式发挥作用,具有增强的肿瘤和免疫调节活性。

  • GC39174 structure
    GC39174EC359
    CAS: 2012591-09-0
    纯度: >99.00%

    EC359 是一种有效的,选择性的,高亲和力的和口服的生物利用度白血病抑制因子受体 (LIFR) 抑制剂,其 Kd 值为 10.2 nM,可直接与 LIFR 相互作用以有效阻断 LIF/LIFR 相互作用。

  • GC39175 structure
    GC39175SR-4835
    CAS: 2387704-62-1
    纯度: >99.50%

    SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13 with IC50 of 99 nM and Kd of 98 nM for CDK12 and IC50 of 4.9 nM for CDK13. SR-4835 disables triple-negative breast cancer (TNBC) cells. SR-4835 promotes synergy with DNA-damaging chemotherapy and PARP inhibitors.